Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VC005 tablets for non-segmental vitiligo (phase II, randomized, double-blind, placebo-controlled)
ChiCTR2500111807Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VC-005 in Vitiligo (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: Percent change from baseline in facial vitiligo area score index (F-VASI) at Week 24. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
VC-005
03
Conditions
Vitiligo
Beyond the preview
Go deeper on ChiCTR2500111807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111807.